# Clinical Assessment of GSK716155 for Type 2 Diabetes Mellitus

> **NCT00530309** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 40 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** GSK716155 for injection
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00530309
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08-01
- **Primary completion:** 2008-04-17
- **Final completion:** 2008-04-17
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2017-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00530309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00530309, "Clinical Assessment of GSK716155 for Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00530309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*